Andrew Hykes
CIK 1806431 · President and CEO · last filed 2026-10-06
Andrew Hykes is a President and CEO who has filed 71 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing shows the insider was granted $13.1K of SI on Oct 6, 2026. Across all open-market trades the lifetime net is −$34.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $147.8K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NARI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
9 PARKER AVENUE, SUITE 100
IRVINE, CA 92618
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SI | Director | 7,438 | $19.88 | $147.8K | $0 | 2 | 2026-10-06 |
| Inari Medical, Inc. (NARI) Delisted | President and CEO | 0 | $79.97 | $0 | -$34.09M | 64 | 2025-02-19 |
Recent Filings
71 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-06 | SI | Grant (A) | +669 | $13.1K | EDGAR |
| 2026-06-29 | SI | Grant (A) | +5,046 | $0 | EDGAR |
| 2025-02-19 | Inari Medical, Inc. (NARI) Delisted | Mixed | −702,894 | $0 | EDGAR |
| 2025-02-12 | Inari Medical, Inc. (NARI) Delisted | Exer (M) | +194,538 | $184.6K | EDGAR |
| 2025-02-06 | Inari Medical, Inc. (NARI) Delisted | Grant (A) | +67,282 | $0 | EDGAR |
| 2025-01-03 | Inari Medical, Inc. (NARI) Delisted | Tax (F) | −4,409 | -$225.1K | EDGAR |
| 2024-12-20 | Inari Medical, Inc. (NARI) Delisted | Sell (S) | −3,000 | -$165.9K | EDGAR |
| 2024-11-22 | Inari Medical, Inc. (NARI) Delisted | Sell (S) | −3,000 | -$152.5K | EDGAR |
| 2024-10-31 | Inari Medical, Inc. (NARI) Delisted | Sell (S) | −3,000 | -$150.0K | EDGAR |
| 2024-10-29 | — | Notice (144) | −9,000 | -$383.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.